175 results about "Therapeutic group" patented technology

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

Provided herein are methods of training an algorithm for adaptive predictive enrichment of a randomized controlled trial (RCT). The method includes providing an RCT with at least one primary outcome; defining an interim analysis timepoint; at the interim analysis timepoint, defining individualized estimates of the effects of a studied intervention for the primary outcome, as compared to a control arm, through iterative analysis; and training a machine-learning algorithm to identify one or more signatures of individualized treatment response in a treatment group as compared to a control group; where the one or more signatures of individualized treatment response are used to recommend predictive enrichment for subsequent RCT enrollment. Also provided herein is a method of adaptive predictive enrichment of a RCT including applying the algorithm trained above.

The invention discloses a mouse model for treating in-situ pulmonary nodules by using bacterial lysates as well as a construction method and application of the mouse model. The method comprises the following steps: constructing an in-situ pulmonary nodule KT mouse model, instilling adenovirus, randomly dividing the model into an in-situ pulmonary nodule control group and a treatment group, performing bacterial lysate administration on mice in the treatment group at the maximum treatment dosage of 35mg / kg / d, and administering the same dosage of PBS solution to the control group. According to the invention, the possibility of killing cancer cells and preventing precancerous lesion progression by promoting autoimmunity of mice through oral immunostimulation drugs is provided for the first time, namely, the curative effect and mechanism of new drugs are researched through a mouse model, so that the clinical indications of the drugs are widened, and the blank field of clinical pulmonary nodule drug treatment is supplemented.

The invention relates to the technical field of intelligent wearing monitoring, in particular to a multifunctional head-mounted device for improving anxiety and depression symptoms in the perioperative period, which comprises a main body base, an electric treatment assembly and a power supply assembly are arranged on the main body base, extending ear hooks are arranged at two ends of the main body base, binding straps are arranged on the extending ear hooks, and a nose pad block is arranged at the bottom of the main body base. The electric treatment assembly is in signal connection with an evaluation and control system, heart rate monitoring assemblies are arranged on the extension ear hooks, and an eye movement monitoring assembly is arranged at the bottom of the main body base; a displacement monitoring assembly is arranged on the main body base, and a respiration monitoring assembly is arranged on the nose pad block. According to the invention, physiological parameter monitoring, anxiety and depression assessment and percutaneous nerve stimulation treatment functions are integrated, and multi-node fixed design and real-time dynamic data processing are combined, so that redundant steps depending on preposed medical assessment in the traditional technology are omitted, doctors can remotely and accurately adjust personalized schemes based on dynamic data, and the accuracy of diagnosis and treatment is improved. The anxiety depression intervention efficiency and reliability in the perioperative period are improved.

The invention discloses an application of pentagalloylglucose (PGG) in preparation of a medicine for resisting doxorubicin cardiotoxicity. The method comprises the following steps: inducing doxorubicin (DOX), establishing a myocardial cell H9C2 injury model, and determining the DOX-induced myocardial cell injury minimum concentration; after 20 [mu] M of PGG is added into a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, and compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and ejection fraction (EF%) of mice in the doxorubicin and pentagalloylglucose group are remarkably increased, the myocardial fiber structure is improved, the cytoplasm vacuolation is reduced, the serum cTnT and BNP levels are reduced, and the ROS level is reduced. The experiment proves that the pentagalloylglucose can obviously reduce the cardiotoxicity induced by the DOX.

The invention discloses an application of hydroxygenkwanin (HGK) in preparation of a drug for preventing and treating cardiotoxicity induced by antitumor drugs. The method comprises the following steps: inducing doxorubicin (DOX), establishing a myocardial cell H9C2 injury model, and determining the DOX-induced myocardial cell injury minimum concentration; after 20 [mu] M of HGK is added into a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, and compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and ejection fraction (EF%) of mice in the doxorubicin and hydroxygenkwanin group are remarkably increased, the myocardial fiber structure is improved, the cytoplasm vacuolation is reduced, the levels of serum cTnT, CK-MB and BNP are reduced, and the ROS level of heart tissue is reduced. Therefore, the hydroxygenkwanin can obviously reduce the cardiotoxicity induced by the DOX.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are histotripsy and / or ultrasound transducer arrays, and associated systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. The transducer arrays provided herein can include a machined array shell having a plurality of wells formed therein. An acoustic stack including a plurality of matching and transducer elements can be disposed in the wells and be configured to transmit ultrasound energy through the plurality of matching layers and through the array shell towards a common focal point

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are histotripsy and / or ultrasound transducer arrays, and associated systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. The transducer arrays provided herein can be individually tuned such that transducer arrays with different sizes, focal lengths, or transducer element sizes may work at a desired operating frequency with the same signal generator.

Disclosed herein are exemplary medical devices for controlled delivery of material compositions, particularly occlusive, therapeutic, or diagnostic compositions. Medical devices disclosed herein comprise components for maintaining a stationary position, for providing catheters at a precise step in a method, for inflating or deflating a balloon, if present, and for providing a composition to a target site.

The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agenst capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol+phenformin.

Provided is a process including: accessing clinical trial data of an ongoing clinical trial that is not yet complete, the clinical trial having a plurality of treatment groups and a plurality of patients in the treatment groups; detecting, with an anomaly detection model, an anomaly in the clinical trial data for a first patient, the anomaly corresponding to a first patient among the plurality of patients; in response to detecting the anomaly classifying the first patient as anomalous in the trial; generating, with the computer system, by an artificial intelligence model, a candidate explanation for the detected anomaly by designating data in a record for the first patient as potentially correlated with the anomaly; and causing the anomaly and the candidate explanation to be presented to a data safety monitoring board (“DSMB”) of the clinical trial.

The invention discloses an application of rapamycin in preparation of a composition for treating a hereditary spastic paraplegia SPG subtype. The rapamycin can obviously improve the motion disorder and pathological injury phenotype of an SPG80 subtype mammal model, improve the lysosome function and promote the autophagy process through mTOR inhibition, provides specific intervention for nerve cell apoptosis and a glial cell abnormal activation mechanism caused by UBAP1 deletion, fills the blank that no effective treatment means exists for the SPG subtype, and has a good application prospect. A theoretical basis is provided for clinical treatment of patients, and a reference is provided for other SPG variations (such as SPG3A).

Apparatuses, systems, and methods for treating a tissue site. A system for treating a tissue site with negative pressure includes a dressing and a dressing interface. The dressing includes a cover configured to be disposed over the tissue site, a tissue interface configured to be positioned adjacent to the cover, and a wound contact layer configured to be positioned adjacent to the tissue interface. The dressing interface is configured to be coupled to the cover to fluidly couple the tissue interface and the wound contact layer to a therapy unit. The dressing interface is also configured to transmit electromagnetic radiation through the cover.

The invention provides cardiovascular intervention postoperative treatment equipment which structurally comprises a lying plate, a moving seat, a telescopic part, a positioning block and a treatment assembly, the lying plate is embedded in the upper middle area of the moving seat, the telescopic part is fixed to the lower middle area in front of the moving seat and is in interval fit with the lying plate, and the positioning block is fixedly connected with the other end of the telescopic part; the treatment assembly is arranged at the upper end of the positioning block and is horizontally communicated with the lying plate; after the lying plate is further improved, the inner side of the plate body is completely covered by the sponge cushion, so that the back bone of a patient can be prevented from being in direct contact with the plate body, and the pain caused by the influence of the hardness of the plate body on the back bone is prevented; then, the infrared positioner on the plate body can be matched with the top part of the treatment assembly in a light induction mode through the infrared generating body of the infrared positioner, so that the cardiovascular treatment area of the patient can be determined through infrared induction instead of medical staff, and therefore the position determination accuracy and efficiency can be improved.

The present disclosure provides therapeutic combinations, which provide a synergistic effect in treating a cancer. The present disclosure provides methods of treatment including administration of the combinations, and uses of the combinations, e.g., for treatment of cancer.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. In particular, provided herein are optimized systems and methods that provide targeted, efficacious histotripsy in a variety of different regions and under a variety of different conditions without causing undesired tissue damage to intervening / non-target tissues or structures.

A histotripsy therapy system configured for the treatment of tissue is provided, which may include any number of features. Provided herein are systems and methods that provide efficacious non-invasive and minimally invasive therapeutic, diagnostic and research procedures. The histotripsy therapy system can include a robotic positioning system configured to move and translate an ultrasound transducer array through a treatment volume.

The invention discloses gelatin hydrogel containing skin cell component seeds as well as a preparation method and application of the gelatin hydrogel, and belongs to the technical field of biomedicine. The iPSCs are used as raw materials, are differentiated into components with full-thickness skin structures and cells, then are coated with gelatin hydrogel, and are transplanted into SD rat bodies, so that inflammatory cells and inflammatory factors can be reduced, the number of epidermal stem cells is increased, fibroblast expression related to scar formation is reduced, and advanced scar formation can be inhibited. The treatment effect of the method is most obvious on the third day, the size of the wound is obviously smaller than that of a frostbite group, and the wound of a treatment group is completely healed on the seventh day, which shows that wound closure can be accelerated and infection can be reduced after treatment by the method.

The application discloses application of pentagalloyl glucose (PGG) in preparation of an anti-doxorubicin cardiotoxicity medicine. The process is as follows: a myocardial cell H9C2 injury model is induced and established by doxorubicin (DOX), and a minimum concentration of the myocardial cell injury induced by DOX is determined. After 20 muM of PGG is added to a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and the ejection fraction (EF%) of mice in the doxorubicin+pentagalloyl glucose group are significantly increased, the myocardial fiber structure is improved, cytoplasm vacuolization is reduced, the serum cTnT and BNP levels are reduced, and the ROS level is reduced. It is proved by the above experiments that the pentagalloyl glucose can significantly reduce DOX-induced myocardial toxicity.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

The invention relates to the technical field of clinical application, and discloses preparation and clinical application of Deyu large plaster, the raw materials of the Deyu large plaster comprise fritillaria, deer sinew, honeysuckle and other medicinal materials, yellow lead and sesame oil are supplemented, and the Deyu large plaster is prepared through the steps of preparing and soaking, decocting, adding the yellow lead, removing fire toxin, removing mud, packaging and the like. In the medicinal materials, the fritillaria clears heat and moistens lung, the deer sinew nourishes liver and kidney and strengthens muscles and bones, and the honeysuckle has antibacterial and anti-inflammatory effects, and the medicines are compatible to achieve the effects of strengthening tendons and bones, nourishing blood and dredging collaterals. Clinically, 520 patients with neck, shoulder, waist and leg pain are divided into a treatment group (320 patients use Deyu large plaster) and a control group (200 patients use collateral dredging and pain relieving plaster), after 10 days of treatment course, 102 patients are cured in the treatment group, 131 patients are effective, the total effective rate is 94%, the total effective rate of the control group is 81%, and the difference between the two groups is remarkable (plt: 0.05). The plaster is small in adverse reaction, suitable for long-term use and remarkable in curative effect in treatment of neck-shoulder and lumbocrural pain.

An ergonomic and unobtrusive cardiac monitoring and treatment device with separable monitoring and treatment components includes a first wearable portion, a second wearable portion separable from the first wearable portion, and a device controller. The device controller includes at least one processor and an output device. The first wearable portion includes an elongated strap configured to encircle a thoracic region, ECG sensing electrodes permanently formed into the strap, a driven ground electrode, and conductive wires configured to couple the sensing electrodes with the controller. The second wearable portion includes a wearable substrate configured to be worn over at least one shoulder, one or more treatment electrodes configured to provide a therapeutic shock to the patient, and at least one additional conductive wire configured to releasably connect the treatment electrode(s) to the controller. The output device is configured to provide a notification instructing the patient to wear the second wearable portion.

The present invention addresses the problem of providing: a novel treatment strategy using a molecular targeted drug in cancer patients having a driver mutation; a novel method capable of identifying a treatment target patient group suitable for the novel treatment strategy, and capable of predicting, monitoring, or diagnosing a response to the novel treatment strategy; and a kit for use in the method. The present invention provides, as a means for solving the problem, a pharmaceutical composition which contains, as an active ingredient, a FAK inhibitor and a RAF / MEK dual inhibitor for use in the treatment of, for example, patients suffering from cancer, and which is for administration to patients who have been confirmed that an epithelial biomarker expression level in a tumor sample isolated from a patient is higher than the mesenchymal biomarker expression level.

To provide a medical system and the like that can detect a contact state between a treatment tool and a tissue from an endoscope image.SOLUTION: A medical system 1 includes a memory 120 which stores a trained model 122, and a processor 110. The trained model 122 is a model trained by training data including an endoscopic image and a contact state between a treatment tool and a tissue in the endoscopic image. The endoscopic image is captured by an endoscope which captures an image including the treatment tool and a tissue to be treated. The processor 110 acquires the endoscopic image including the treatment tool and the tissue. The processor 110 uses the trained model to detect, from the endoscopic image, the contact state between the treatment tool and the tissue as first information.SELECTED DRAWING: Figure 2

The invention discloses an adaptive random-based clinical test allocation method, system and device, and a storage medium, and the method comprises the steps: randomly allocating subjects to each treatment group according to a preset proportion, and obtaining the current curative effect data of each treatment group; determining the posterior probability of each treatment group based on the current curative effect data of each treatment group, and adjusting the random distribution probability according to the posterior probability; determining the condition test efficiency of each treatment group, and executing a preset resource optimization strategy on each treatment group according to the condition test efficiency to obtain a test result; and determining the current posterior probability of each treatment group according to the test result, and determining the optimal treatment group based on the current posterior probability. The random distribution probability of each treatment group is dynamically adjusted in the test process, the preset resource optimization strategy is executed on each treatment group according to the condition test efficiency, and the target treatment group is determined based on the test result, so that the subject distribution in the test is optimized, and the reliability and the accuracy of the test result are improved.

A device may establish communication between the plurality of intelligent injection devices and an artificial intelligence-powered clinical research platform configured to manage a clinical trial or research program. A device may analyze, via the artificial intelligence platform, clinical trial protocol requirements including study design parameters, randomization schemes, blinding protocols, and adverse event monitoring requirements to generate coordinated medication administration strategies across the plurality of intelligent injection devices. A device may apply research protocol constraints to restrict medication selection, dosage calculations, administration timing, and patient assignment across the plurality of intelligent injection devices. A device may generate real-time coordination instructions through the artificial intelligence platform including synchronized administration timing across multiple sites, dosage verification protocols for different treatment arms, and compliance monitoring procedures tailored to specific research protocol requirements.

The invention belongs to the technical field of nanotechnology, and relates to a preparation method and application of ferrocene-loaded electroactive mesoporous silica composite nanoparticles. Specifically, MSNs are constructed as a template, elemental platinum is subjected to in-situ reduction and loaded on the MSNs, and ferrocene is used as an electroactive group, so that the Fc / Pt-coated MSNs (FPMSN) nanoparticles with electroactivity are successfully synthesized. A HepG2 tumor-bearing nude mouse model is constructed, FPMSNs combined electrodynamic therapy antibody internal tumor effect research is carried out, and tumor growth is proved to be effectively inhibited by FPMSNs combined electrodynamic therapy through weight and tumor volume measurement of tumor-bearing nude mice in different treatment groups. The obvious effectiveness and good biological safety of the FPMSNs electrodynamic therapy provide a new way for developing a new cancer treatment method.

The application of FBH1 protein in judging the efficacy of postoperative somatostatin analogue adjuvant therapy for pancreatic neuroendocrine tumors relates to the fields of proteomics and clinical detection technology. The present invention finds that the disease-free survival and total survival time of the postoperative SSA adjuvant therapy group of PNETs patients with high FBH1 expression are significantly better than those of the non-adjuvant therapy group. By detecting the relative content of FBH1 protein in the tumor tissue of PNETs patients, it is effective to evaluate whether the patients use SSA drug adjuvant therapy after surgery, which is of great significance for the guidance of postoperative medication for patients.